Fredag 6 November | 10:49:15 Europe / Stockholm
Svenska | English
Est. tid*
2026-11-20 07:00 Kvartalsrapport 2026-Q3
2026-08-21 - Kvartalsrapport 2026-Q2
2026-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2026-05-22 - Årsstämma
2026-05-21 - Kvartalsrapport 2026-Q1
2026-02-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-19 - X-dag ordinarie utdelning PAX 0.00 SEK
2025-05-16 - Årsstämma
2025-05-16 - Kvartalsrapport 2025-Q1
2025-04-08 - Extra Bolagsstämma 2025
2025-02-21 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning PAX 0.00 SEK
2024-05-23 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2023-05-24 - Årsstämma
2023-05-24 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning PAX 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning PAX 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning PAX 0.00 SEK
2020-05-27 - Årsstämma
2020-05-27 - Kvartalsrapport 2020-Q1
2020-02-21 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning PAX 0.00 SEK
2019-05-23 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2018-05-24 - Årsstämma
2018-05-24 - Kvartalsrapport 2018-Q1
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Paxman är verksamt inom skalpkylning, som används för patienter som behandlas för cytostatika. Bolagets produkt Paxman Scalp Cooler används för att minimera håravfallet hos patienten under behandlingens gång. Scalp Coolern är en fristående, mobil och eldriven kylenhet som kyler ner patientens hårbotten via en kylmössa. Paxman grundades år 1996 och har sitt huvudkontor i Karlshamn.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Invitation: Presentation with Richard Paxman – Q3 2026

2026-11-06 08:00:00

PAXMAN will publish its report for the third quarter of 2026 on 20 November. A presentation for investors, analysts and the media will be published on the same day at 9:00 a.m. CET.

During the presentation, CEO Richard Paxman will comment on the report. The Q&A session will be moderated by Maria Karlsson Osipova. The presentation will be held in English.
Questions may be submitted in advance to Maria Karlsson Osipova (maria.karlsson.osipova@dnbcarnegie.se) - these questions will be addressed during the presentation. Written questions received on 20 November will be compiled and forwarded to the company, with a written Q&A to be published subsequently.
The presentation can be accessed on https://www.youtube.com/@DNBCarnegiePlay at 9:00 a.m. CET on the 20th of November. 

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: Richard.Paxman@paxmangroup.com
https://investor.paxmangroup.com/

About Us

Paxman Group is a global medical technology company focused on improving quality of life for people undergoing chemotherapy through innovative side-effect management solutions. Its portfolio addresses two of the most challenging treatment-related side effects: chemotherapy-induced alopecia (hair loss) and chemotherapy-induced peripheral neuropathy (CIPN).

Paxman Group’s scalp cooling technologies, including the Paxman Scalp Cooling System and the DigniCap Scalp Cooling System, are used globally in hospitals and cancer centres to support patients undergoing chemotherapy by helping to reduce the risk of chemotherapy-induced hair loss. The clinically validated Paxman Neuropathy System supports the prevention of CIPN through cryocompression technology.

Founded through the Paxman family's personal experience of cancer treatment, Paxman Group works with patients, clinicians and research partners to advance side effect management in cancer care globally.

PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden). Subsidiaries of the PAXMAN Group are Paxman Coolers Limited (Huddersfield UK), Paxman Inc. (Houston, Texas US), Paxman Canada (Toronto, Ontario CA), Dignitana AB (Lund, Sweden), Dignitana Inc. (Dallas, TX US), and Dignitana S.r.l. (Milan, IT).

Paxman AB (publ) is listed on Nasdaq First North Growth Market with FNCA Sweden AB as Certified Adviser.

Attachments

Invitation: Presentation with Richard Paxman – Q3 2026

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden